The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Activation of the Peripheral Endocannabinoid System in Human Obesity
Open accessAbstract
Obesity is the main risk factor for the development of type 2 diabetes. Activation of the central endocannabinoid system increases food intake and promotes weight gain. Blockade of the cannabinoid type 1 (CB-1) receptor reduces body weight in animals by central and peripheral actions; the role of the peripheral endocannabinoid system in human obesity is now being extensively investigated. We measured circulating endocannabinoid concentrations and studied the expression of CB-1 and the main degrading enzyme, fatty acid amide hydrolase (FAAH), in adipose tissue of lean (n = 20) and obese (n = 20) women and after a 5% weight loss in a second group of women (n = 17). Circulating levels of anandamide and 1/2-arachidonoylglycerol were increased by 35 and 52% in obese compared with lean women (P < 0.05). Adipose tissue mRNA levels were reduced by -34% for CB-1 and -59% for FAAH in obese subjects (P < 0.05). A strong negative correlation was found between FAAH expression in adipose tissue and circulating endocannabinoids. Circulating endocannabinoids and CB-1 or FAAH expression were not affected by 5% weight loss. The expression of CB-1 and FAAH was increased in mature human adipocytes compared with in preadipocytes and was found in several human tissues. Our findings support the presence of a peripheral endocannabinoid system that is upregulated in human obesity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“and this effect is likely to result from downregulation of FAAH gene expression, an effect which has also been observed in adipocytes sampled from obese women.110”
From Cannabinoids as Pharmacotherapies for Neuropathic Pain: From the Bench to the Bedside (2009) · cites this paper as [110]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873
Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery
Sjöström, L., Lindroos, A.-K., Peltonen, M., Torgerson, J., Bouchard, C., Carlsson, B., Dahlgren, S., Larsson, B., Narbro, K., Sjöström, C. D., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa035622 · Cited by 4,457
Ledent, C. A., Valverde, O., Cossu, G., Petitet, F., Aubert, J.-F., Beslot, F., Böhme, G. A., Impérato, A., Pedrazzini, T., Roques, B. P., et al. (1999) · Science · doi:10.1126/science.283.5400.401 · Cited by 3,628
International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors
Howlett, A. C., Barth, F., Bonner, T. I., Cabral, G., Casellas, P., Devane, W. A., Felder, C. C., Herkenham, M., Mackie, K., Martin, B. R., et al. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.2.161 · Cited by 2,819
The molecular logic of endocannabinoid signalling
Piomelli, D. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1247 · Cited by 1,957
Leptin-regulated endocannabinoids are involved in maintaining food intake
Di Marzo, V., Goparaju, S. K., Wang, L., Liu, J., Bátkai, S., Járai, Z., Fezza, F., Miura, G. I., Palmiter, R. D., Sugiura, T., et al. (2001) · Nature · doi:10.1038/35071088 · Cited by 1,559
Gaal, L. F. V., Rissanen, A., Scheen, A. J., Ziegler, O., & Rössner, S. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66374-x · Cited by 1,511
Cota, D., Marsicano, G., Tschöp, M. H., Grübler, Y., Flachskamm, C., Schubert, M. I., Auer, D. P., Yassouridis, A., Thöne‐Reineke, C., Ortmann, S., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17725 · Cited by 1,168
Osei‐Hyiaman, D., DePetrillo, M. A., Pacher, P., Liu, J., Radaeva, S., Bátkai, S., Harvey-White, J. D., Mackie, K., Offertáler, L., Wang, L., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23057 · Cited by 1,131
Body Mass Index, Waist Circumference, and Health Risk
Janssen, I., Katzmarzyk, P. T., & Ross, R. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.18.2074 · Cited by 969
Cited by
Sorted by citations
Items 601–694 of 694
The role of Endocannabinoid System in pathogenesis and therapy of obesity
Pyszniak, M., Pogoda, K., & Mazur, A. (2014) · Pediatric Endocrinology · doi:10.18544/ep-01.13.02.1487 · Cited by 1
Les approches thérapeutiques non invasives de l’obésité : hier, aujourd’hui et demain
Galmiche, M. C., & Déchelotte, P. (2022) · Nutrition Clinique et Métabolisme · doi:10.1016/j.nupar.2022.09.001 · Cited by 1
Il sistema endocannabinoide e l’obesità: prospettive terapeutiche
Pagotto, U., Cervino, C., Bellocchio, L., Vicennati, V., & Pasquali, R. (2007) · L Endocrinologo · doi:10.1007/bf03344556 · Cited by 1
Medikamentöse Therapie der Adipositas
May, M., & Jordan, J. (2015) · Springer eBooks · doi:10.1007/978-3-642-54573-3_68 · Cited by 1
Modification of Cardiometabolic Risk Through Cannabinoid Type-1 Receptor Antagonism
Andrikopoulos, G. K., & Tzeis, S. M. (2008) · Angiology · doi:10.1177/0003319708320938 · Cited by 1
“Endocannabinoids also exert peripheral effects mediated by the activation of peripheral CB1 receptors, which are mainly located in adipose tissue, gastrointestinal system, liver, pancreas, pituitary gland, and adrenal glands.(15,16) Mutant mice lacking CB1 receptors display hypophagia and body weight reduction, while…”
BackgroundObesity as a risk factor in venous thromboembolism
Stein, P. D. (2016) · doi:10.1002/9781119039112.ch20 · Cited by 1
Reddy, R., & Singh, I. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.30.630715 · Cited by 1
Abbott, S. K. (2011) · Research Online (University of Wollongong)
Cardiovascular Risk and the Endocannabinoid System
Early, J. L., & Ablah, E. A. (2008) · Kansas Journal of Medicine · doi:10.17161/kjm.v1i2.10762
A obesidade diminui a resposta de artérias mesentéricas de resistência a agonistas canabinóides.
Lobato, N. D. S. (2010) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.42.2010.tde-14012011-162359
Analyse des Fettsäureamidhydrolasegens bei extrem adipösen Kindern und Jugendlichen
Wandolski, M. (2010) · DuEPublico (University of Duisburg-Essen)
The endocannabinoid system as a target for obesity treatment
Khan, M. A. N., & Wilding, J. P. H. (2008) · Birkhäuser Basel eBooks · doi:10.1007/978-3-7643-7425-9_6
The endocannabinoid system: a therapeutic target in patients with abdominal obesity?
Haslam, D. B. (2008) · Future Prescriber · doi:10.1002/fps.9
The Endocannabinoid System: A Promising Novel Mechanistic Pathway in the Cardiometabolic Syndrome
Al‐Jaghbeer, E., Khraisat, A. S., & Singh, S. P. (2008) · Journal of the CardioMetabolic Syndrome · doi:10.1111/j.1559-4572.2008.06448.x
Maldonado, R. J. (2008) · Medicina Clínica · doi:10.1157/13120341
Fulmer, T. (2008) · Science-Business eXchange · doi:10.1038/scibx.2008.743
El sistema endocannabinoide como diana para reducir el riesgo cardiometabólico y la obesidad
Vigoa, A. V., Álvarez, N. M. C., Cruz, A. V., Rosabal, A. M., & Fernández‐Alfonso, M. S. (2009) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/s0214-9168(09)71132-5
“2009;21(3):151-6 153 de manera que la sobreactividad del SEC se consi-dera la causa y no la consecuencia de la obesidad, ya sea subcutánea o visceral 32,33 .”
De la prise en charge du diabète à la prévention des événements cardiovasculaires
Solignac, M. (2007) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(07)74160-3
Abdominal obesity, cardiometabolic risk and endocannabinoid system
Bon, G. B. (2013) · Italian Journal of Medicine · doi:10.4081/itjm.2007.3.49
n-3 Fatty acid derived endocannabinoids: a new link between fish oil and inflammation
Balvers, M. G. J. (2012) · doi:10.18174/202605
Il sistema endocannabinoide e il controllo del metabolismo energetico: fisiologia e fisiopatologia
Pagotto, U., Vicennati, V., & Pasquali, R. (2008) · Giornale italiano di cardiologia · doi:10.1714/669.7816
Vascular risk factors and adipocyte dysfunction in metabolic syndrome
Hajer, G. R. (2008) · Utrecht University Repository (Utrecht University)
Endocannabinoids and cardiovascular prevention: real progress?
Nodari, S., Manerba, A., Metra, M., & Cas, L. D. (2007) · Heart International · doi:10.4081/hi.2007.27
“In obese women, with no others comorbidities, and whose cause of obesity was correlated to alimentary disorders or to the menopause, AEA and 2-AG levels were significantly greater than in the control group (17) (Fig.”
BackgroundEffects of immunosuppressive drugs on human adipose tissue metabolism
Pereira, M. J. (2012) · Gothenburg University Publications Electronic Archive (Gothenburg University)
The endocannabinoid system, Obesity, and insulin resistance
Engeli, S. (2008) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-008-0014-3
“Matias et al. [22] Engeli et al. [ 25 ] Lofgren et al. [31] Bluher et al. [38••] Cote et al. [39••] Obese humans AT: on AT: FAAH o Blood: 2-AG m”
BackgroundShort Title: GL/FFA Cycle and Signaling
Prentki, M., & Madiraju, S. R. M. (2008)
endocannabinoids and related lipids in the subcutaneous adipose tissue of obese diabetic patients
Annuzzi, G., Piscitelli, F., Marino, L. D., Patti, L., Giacco, R., Costabile, G., Bozzetto, L., Riccardi, G., Verde, R., Petrosino, S., et al. (2010)
The Role of Adipocyte Insulin Resistance in the Pathogenesis of Obesity-Related Elevations in
D'Eon, E. M., Pierce, K. A., Roix, J. J., Tyler, A. R., Chen, H., & Teixeira, S. R. (2008)
Pathogenesis of the metabolic syndrome and the influence of cannabinoids
Marzo, V. D., Kunos, G., Bergman, R. N., Després, J., & Brewer, B. (2008)
Endocannabinoids and skeletal muscle glucose uptake.
Cavuoto, P. (2010) · Adelaide Research & Scholarship (AR&S) (University of Adelaide)
Blood Pressure Regulation by the Endocannabinoid System in Conditions Associated with Hypertension
Schaich, C. L. (2014) · WakeSpace Scholarship (Wake Forest University)
Dietary linoleic acid induces obesity through excessive endocannabinoid activity
Alvheim, A. R. (2012) · NORA - Norwegian Open Research Archives
Roberge, C., Carpentier, A. C., Langlois, M., Baillargeon, J., Ardilouze, J., & Gallo‐Payet, N. (2007)
Almada, M., Soares, A. L. P. P. D. P., & Correia‐da‐Silva, G. (2013)
Obesity, Intestinal Gut Barrier and Microbiota: an Emerging Frontier on Energy Metabolism
Rua São Francisco Xavier, 5. –. P., & Kraemer-Aguiar, L. G. (2016) · Journal of Gastrointestinal Disorders and Liver Functions · doi:10.15436/2471-0601.16.722
Metabolic Regulation by Lipid Activated Receptors
Ruby, M. A. (2010) · eScholarship (California Digital Library)
Kubicek, G. J., Reddy, E. K., Kimler, B. F., Al-Kasspooles, M. F., Baranda, J., Wang, F., Krishnan, L., & Jewell, W. R. (2008) · Kansas Journal of Medicine · doi:10.17161/kjm.v1i2.10758
Carvalho, K. M. M. B. (2015) · Americanae (AECID Library)
Um, H. P. N., Kowalczyk, Z., Sałagacka-Kubiak, A., & Balcerczak, E. I. (2015)
Food reward from a behavioural and (neuro)physiological perspective
de Bruijn, S. E. M. (2017) · doi:10.18174/421669
Stöckli, R., & Keller, U. (2008) · Forum Médical Suisse ‒ Swiss Medical Forum · doi:10.4414/fms.2008.06486
Endocannabinoid metabolism : the impact of inflammatory factors and pharmacological inhibitors
Karlsson, J. (2018) · KTH Publication Database DiVA (KTH Royal Institute of Technology)
Mahmoud, M. M. (2015) · OpenCommons at University of Connecticut (University of Connecticut)
Anandamide Level in Men with Oligoasthenoteratozoospermia
Taieb, M. A. E., Ali, A. M. A., Sedeek, M. H., & Hussein, A. A. (2020) · The Egyptian Journal of Hospital Medicine · doi:10.21608/ejhm.2020.123482
“In addition, obese menopausal women were found to have increased plasma AEA and 2-AG levels compared to lean women of similar age ((28)).”
BackgroundMarzo, V. D., Kunos, G., & Scherer, T. (2020) · eLife · doi:10.7554/elife.60771.sa1
Demidova, T. Y., Krasilnikova, E. I., Владиславович, В. С., Моругова, Т. В., & Adasheva, T. V. (2021) · Terapevticheskii arkhiv · doi:10.26442/00403660.2021.08.200898
“Эффективность Диетрессы у данной категории пациентов, вероятно, обусловлена тем, что точкой приложения препарата является ЭКС, которая вовлечена в процесс ожирения на ранних этапах заболевания [29, 30].”
Metabolic health and vascular function in adults
Tischmann, L. (2021) · Research Publications (Maastricht University) · doi:10.26481/dis.20210428lt
Current literature in diabetes
(2006) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.659
Rimonabant: a guide to its use in obese and overweight patients
&NA; (2007) · Drugs & Therapy Perspectives · doi:10.2165/00042310-200723080-00002
Dietary fatty acids modulate the endocannabinoid system in rat submandibular glandPreprint
Herrera, C. C., Blanco, M., Repossi, G., Nackauzi, J. E., & Actis, A. B. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.04.25.489419
Endocannabinoids and Cardiovascular Prevention: Real Progress?
Nodari, S., Manerba, A., Metra, M., & Cas, L. D. (2007) · Heart International · doi:10.1177/1826186807003001-204
Medikamentöse Therapie der Adipositas
Jordan, J. (2008) · Springer eBooks · doi:10.1007/978-3-540-76882-1_55
Therapeutic implications of the endocannabinoid system in neurodegenerative diseases
Goren, A., & University of Rome "G.Marconi" (2015) · Clinical Case Reports and Reviews · doi:10.15761/ccrr.1000126
“CB1 receptors are one of the most abundant G-protein-coupled receptors in the mammalian brain, but they are also expressed in peripheral tissues (including myocardium, human coronary artery endothelial and smooth muscle cells, adipose tissue and various cell types of the liver) [25-29].”
BackgroundReduced BMI in Cannabis users: Regulation, mechanisms, and public health impact
Clark, T. M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-90036-2.00002-8
The Bioactive Components of Cannabis
Ross, I. A. (2023) · Springer eBooks · doi:10.1007/978-3-031-35155-6_4
Zhang, C., Xu, R.-Q., Wang, X.-Q., Sun, L., Mo, P., Cai, R.-J., Lin, X., Luo, C.-F., Ou, W., Lu, L., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24030952
Zhang, C., Xu, R.-Q., Wang, X.-Q., Sun, L., Mo, P., Cai, R.-J., Lin, X., Luo, C.-F., Ou, W., Lu, L., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24030955
Santos, N. M. H. D. O. (2024) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2024.tde-07082024-163629
Kumrić, M., Dujić, G., Vrdoljak, J., Šupe‐Domić, D., Dujić, Ž., & Božić, J. (2025) · Cannabis and Cannabinoid Research · doi:10.1177/25785125251392773
Lindborg, K. A. (2010) · UA Campus Repository (The University of Arizona)
Zhang, C., Xu, R., Wang, X.-Q., Sun, L.-F., Mo, P., Cai, R.-J., Lin, X., Luo, C.-F., Ou, W.-C., Lu, L.-J., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24030946
Zhang, C., Xu, R., Wang, X.-Q., Sun, L.-F., Mo, P., Cai, R.-J., Lin, X., Luo, C., Ou, W., Lu, L.-J., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24030940
Zhang, C., Xu, R., Wang, X.-Q., Sun, L.-F., Mo, P., Cai, R.-J., Lin, X., Luo, C., Ou, W.-C., Lu, L.-J., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24030943
Zhang, C., Xu, R., Wang, X.-Q., Sun, L.-F., Mo, P., Cai, R.-J., Lin, X., Luo, C., Ou, W., Lu, L.-J., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24030949
Zhang, C., Xu, R., Wang, X.-Q., Sun, L.-F., Mo, P., Cai, R.-J., Lin, X., Luo, C., Ou, W., Lu, L.-J., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24030937
Onimus, O., de Almeida, C., Bertrand, B., Castel, J., Mashhour, N., Ansoult, A., Luquet, S. H., & Gangarossa, G. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.10.693401
“…in the ECS peripheral tone, as evidenced by the upregulation of ECS-related signaling machinery and CB1R in some peripheral organs [14,44,52,53] but also in the nodose ganglia of HFD-fed mice (current study), a region that houses the sensory neurons of the vagus nerve and integrates…”
Jourdan, T. (2010) · theses.fr (ABES) · doi:10.70675/8269f4dfz220bz4008z842bzb4165efa617c
“La production et la dégradation des EC sont des phénomènes très rapides (Engeli et al., 2005).”
BackgroundBrissard, L. (2018) · theses.fr (ABES) · doi:10.70675/24feb632zea3az4ccbz92e9z6c3512519f0f · Cited by 1
Şen, B., Ulusoy, E., Darcan, M., Ergun, M., Lobentanzer, S., Rifaioğlu, A. S., Türei, D., Sáez-Rodríguez, J., & Doğan, T. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.12.718028 · Cited by 2
“Both genes were associated with metabolic and cardiovascular conditions such as diabetes and cardiovascular disease, supported by multiple studies 27–34 .”
Onimus, O., de Almeida, C., Bertrand, B., Castel, J., Mashhour, N., Ansoult, A., Luquet, S. H., & Gangarossa, G. (2026) · British Journal of Pharmacology · doi:10.1111/bph.70507 · Cited by 1
“Eating disorders and obesity are associated with a chronic elevation of circulating endocannabinoids, particularly 2-arachidonoylglycerol (2-AG) and/or AEA, in both humans and animal models, reflecting a systemic overactivation of the ECS (Engeli et al., 2005; Little et al., 2018; Matias et al., 2012; Mattelaer et al.…”
InfluentialEndocannabinoid cerebrospinal fluid levels in migraine and its relation to symptoms of depression
Harder, A. V. E., Di, X., Winter, W. M., He, B., van Dongen, R. M., Onderwater, G. L. J., van Zwet, E. W., Krekels, E. H. J., Köhler, I., Ferrari, M. D., et al. (2026) · Cephalalgia · doi:10.1177/03331024261451250
Talebloo, J., Chawla, E., Shahamati, D., Shiv, S., & Gadde, K. M. (2026) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2026.2713043
“Individuals with obesity often exhibit elevated circulating endocannabinoid levels, as well as changes in expression and activity of ECS components in metabolically relevant tissues, indicating a state of chronic ECS overactivation [15,16].”
Can Leptin Responsiveness Be Restored in Common Human Obesity?
Janssen, J. A. M. J. L. (2026) · Lipidology · doi:10.3390/lipidology3030024
de Almeida, I. D. F. R., Zago, A., Lorenzett, A. K. P., Peczek, S. H., Babinski, T. P., de Lima, V. A., & Mainardes, R. M. (2026) · Future Pharmacology · doi:10.3390/futurepharmacol6040051
Barbosa, R., Leemput, J., Passilly‐Degrace, P., Pointeau, O., Buch, C., de Barros, J.-P. P., Loriot, M., Lainé, A., Buet, L., Ortega‐Deballon, P., et al. (2026) · Diabetologia · doi:10.1007/s00125-026-06886-0
Choi, H., Han, S., Kim, J., Han, J., 김은수, 허연정, Lee, M., Lee, J., You, H., Lee, S., et al. (2026) · Advanced Science · doi:10.1002/advs.78313
BindingDB (2009) · UC San Diego · doi:10.7270/q2f47mgd
Liver and Fat in Type 2 Diabetes: New Insights and Clinical Relevance
Nandave, M., Ramdhave, A. S., & Goyal, R. K. (2013) · Springer eBooks · doi:10.1007/978-1-4614-9317-4_15
Rola systemu endokanabinoidów w patogenezie i terapii otyłości
Pyszniak, M., Pogoda, K., Mazur, A., & Tabarkiewicz, J. (2014) · Pediatric Endocrinology
Walker, V. J. (2014) · Deep Blue (University of Michigan)
Metadata
- Authors
- Engeli, S., Böhnke, J., Feldpausch, M., Gorzelniak, K., Janke, J., Bátkai, S., Pacher, P., Harvey-White, J., Luft, F. C., Sharma, A. M., & Jordan, J.
- Affiliations
- Helios Hospital Berlin-Buch (DE)
- Franz Volhard Clinical Research Center, Charité Campus Buch, and HELIOS Klinikum Berlin, Berlin, Germany
- Laboratory of Physiologic Studies, National Institute on Alcohol Abuse & Alcoholism, National Institutes of Health, Bethesda, Maryland
- National Institutes of Health (US)
- McMaster University (CA)
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2005-10-01
- Volume
- 54
- Issue
- 10
- Pages
- 2838-2843
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC2228268
- OpenAlex
- W2162112945
- Cited by
- 686
- References
- 37
- Citations by year
- 2026: 11 · 2025: 14 · 2024: 20 · 2023: 19 · 2022: 20 · 2021: 30 · 2020: 29 · 2019: 24 · 2018: 30 · 2017: 30 · 2016: 15 · 2015: 31 · 2014: 29 · 2013: 29 · 2012: 33
- FWCI
- 38.06
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- MDC Repository (Max-Delbrueck-Center for Molecular Medicine) (submittedVersion)
- Funders
- Sanofi
- Bundesministerium für Bildung und Forschung
- National Institutes of Health
- National Institute on Alcohol Abuse and Alcoholism (Z01AA000375)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- obesity, cannabinoid type 1 receptor, fatty acid amide hydrolase, anandamide, 2-arachidonoylglycerol, adipose tissue, weight loss, human adipocytes, type 2 diabetes risk
- MeSH terms
- Fatty Acid Amide Hydrolases, Adipose Tissue, Amidohydrolases, Arachidonic Acids, Body Composition, Female, Glycerides, Humans, Middle Aged, Obesity, RNA, Messenger, Weight Loss, Gene Expression, Body Mass Index, Linear Models, Postmenopause, Reverse Transcriptase Polymerase Chain Reaction, Receptor, Cannabinoid, CB1, Polyunsaturated Alkamides, Cannabinoid Receptor Modulators, Endocannabinoids
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
